CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

April 23, 2010 updated by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

A Phase 3, Randomized, Open-Label, Comparative Study of CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

The objective of this study is to compare the efficacy and safety of CAELYX versus Paclitaxel HCl in patients with epithelial ovarian carcinoma following failure of first-line, platinum-based chemotherapy. The primary endpoint is time to progression (TTP) following treatment with either CAELYX or Paclitaxel HCl; the secondary endpoints are response rates, time to response, duration of response,quality of life assessment, and survival following treatment with either CAELYX or Paclitaxel HCl. Up to a total of 438 protocol-eligible patients with epithelial ovarian carcinoma following failure of first-line, platinum-based chemotherapy will be enrolled in order to obtain 350 evaluable patients.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

This is a randomized, open-label, comparative study of CAELYX versus Paclitaxel HCl in the treatment of patients with epithelial ovarian carcinoma following failure of first line chemotherapy with a platinum-based regimen. Patients entering the trial will be stratified prospectively for platinum-sensitivity and bulky disease and analyzed retrospectively for prior anthracycline therapy. Protocol-eligible patients, with measurable disease, who have received no more than one prior regimen, which was platinum-based, will be randomized to receive either a one-hour intravenous infusion of CAELYX, 50 mg/m2 every 28 days, or Paclitaxel HCl, 175 mg/m2 as a 3 hour infusion every 21 days. Patients will be treated for up to one year. It is suggested that responding patients receive at least 6 cycles of treatment. Patients with ongoing clinical benefit may continue study drug upon approval of the sponsor as long as it is in the patient's interest and in the absence of severe toxicity. It is suggested that patients exhibiting a complete response (CR) receive 2 subsequent cycles of treatment. Patients exhibiting partial response (PR) may continue to receive study drug as long as therapeutic benefit is being derived but it is suggested that they receive at least 3 subsequent cycles of study drug. Patients will undergo appropriate radiological imaging (x-ray, CT scan, MRI) to document baseline disease, as well as a chest x-ray and an assessment of left ventricular ejection fraction (LVEF) by MUGA scan within 30 days prior to the first dose of study drug. Patients will be followed weekly for hematological toxicities. Radiological imaging will be repeated every 7-8 weeks to assess disease status. Patients who achieve complete or partial response will be reevaluated 4 weeks later to confirm the initial observation of response. All patients will be followed for a minimum of one year for disease progression and survival. LVEF will be assessed by MUGA scan at baseline, when the cumulative anthracycline dose reaches 300 mg/m2 (500 mg/m2 epirubicin), and after every 2 cycles of CAELYX thereafter. Endomyocardial biopsy is recommended for patients who have received > 400 mg/m2 of CAELYX alone or a cumulative anthracycline dose of > 550 mg/m2 (including CAELYX; 900 mg/m2 if epirubicin). [NOTE: This study was initiated on 7-May-1997. Due to poor accrual, the study enrollment was terminated on 31-Aug-1999. Patients were followed until study completion on 12-Apr-2000. During the preparation of the study report (beginning in May 2003), the sites were re-queried for clarification of safety and survival data.]

DOXIL, dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year. Paclitaxel, dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cycle for up to 1 year.

Study Type

Interventional

Enrollment (Actual)

220

Phase

  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Histologically proven (i.e., not borderline) epithelial ovarian carcinoma
  • Measurable disease
  • Recurrence of disease or disease progression indicative of failure of first-line platinum-based chemotherapy
  • Disease-free from prior malignancies for >5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  • Adequate renal creatinine (<2.5 mg/dL (<220 μmol/L)) & liver function (aspartate amino transferase (AST) and alanine amino transferase (ALT) <2 x upper limit of normal, alkaline phosphatase <2.0 x upper limit of normal, except if attributed to tumor, and bilirubin < upper limit of normal)

Exclusion Criteria:

  • Pregnant or breast feeding
  • Life expectancy of <3 months
  • Prior radiation therapy to more than one-third of hematopoietic sites within 30 days prior to first dose of study drug
  • Prior therapy with DOXIL or paclitaxel
  • Prior chemotherapy within 28 days of first dose of study drug (or 42 days if subject has received a nitrosourea or mitomycin)
  • Treated with high dose therapy supported by bone marrow or peripheral stem cell transplantation at any time

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 001
Drug: CAELYX
Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year
Active Comparator: 002
Drug: Paclitaxel HCl
Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To demonstrate noninferiority with respect to time to progression (TTP) for CAELYX/DOXIL treatment when compared to paclitaxel treatment.
Time Frame: 8 week intervals
8 week intervals

Secondary Outcome Measures

Outcome Measure
Time Frame
Response rates, time to response, duration of response,quality of life assessment, and survival following treatment with either CAELYX or Paclitaxel HCl.
Time Frame: one year
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

ALZA
Sequus Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 1997

Study Completion (Actual)

April 1, 2000

Study Registration Dates

First Submitted

April 1, 2008

First Submitted That Met QC Criteria

April 4, 2008

First Posted (Estimate)

April 7, 2008

Study Record Updates

Last Update Posted (Estimate)

April 27, 2010

Last Update Submitted That Met QC Criteria

April 23, 2010

Last Verified

April 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CR004369
  • DOXIL-CAN-301

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ovarian Neoplasms

Clinical Trials on CAELYX

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe